Legal Representation
Attorney
Tiffany D. Gehrke
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 30, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| May 30, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| May 30, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Feb 10, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 10, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 10, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 28, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 18, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
VCTX TWO ELEVEN DF; VCTX TWO ONE ONE DF
Pseudo Mark
VCTX 211 DF
Classification
International Classes
005
042